Cargando…

Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom

OBJECTIVES: To estimate the annual cost to patients, the health service and society of infectious intestinal disease (IID) from Campylobacter, norovirus and rotavirus. DESIGN: Secondary data analysis. SETTING: The United Kingdom population, 2008–9. MAIN OUTCOME MEASURES: Cases and frequency of healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Clarence C, O’Brien, Sarah J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735491/
https://www.ncbi.nlm.nih.gov/pubmed/26828435
http://dx.doi.org/10.1371/journal.pone.0138526
_version_ 1782413086775312384
author Tam, Clarence C
O’Brien, Sarah J
author_facet Tam, Clarence C
O’Brien, Sarah J
author_sort Tam, Clarence C
collection PubMed
description OBJECTIVES: To estimate the annual cost to patients, the health service and society of infectious intestinal disease (IID) from Campylobacter, norovirus and rotavirus. DESIGN: Secondary data analysis. SETTING: The United Kingdom population, 2008–9. MAIN OUTCOME MEASURES: Cases and frequency of health services usage due to these three pathogens; associated healthcare costs; direct, out-of-pocket expenses; indirect costs to patients and caregivers. RESULTS: The median estimated costs to patients and the health service at 2008–9 prices were: Campylobacter £50 million (95% CI: £33m–£75m), norovirus £81 million (95% CI: £63m–£106m), rotavirus £25m (95% CI: £18m–£35m). The costs per case were approximately £30 for norovirus and rotavirus, and £85 for Campylobacter. This was mostly borne by patients and caregivers through lost income or out-of-pocket expenditure. The cost of Campylobacter-related Guillain-Barré syndrome hospitalisation was £1.26 million (95% CI: £0.4m–£4.2m). CONCLUSIONS: Norovirus causes greater economic burden than Campylobacter and rotavirus combined. Efforts to control IID must prioritise norovirus. For Campylobacter, estimated costs should be considered in the context of expenditure to control this pathogen in agriculture, food production and retail. Our estimates, prior to routine rotavirus immunisation in the UK, provide a baseline vaccine cost-effectiveness analyses.
format Online
Article
Text
id pubmed-4735491
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47354912016-02-04 Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom Tam, Clarence C O’Brien, Sarah J PLoS One Research Article OBJECTIVES: To estimate the annual cost to patients, the health service and society of infectious intestinal disease (IID) from Campylobacter, norovirus and rotavirus. DESIGN: Secondary data analysis. SETTING: The United Kingdom population, 2008–9. MAIN OUTCOME MEASURES: Cases and frequency of health services usage due to these three pathogens; associated healthcare costs; direct, out-of-pocket expenses; indirect costs to patients and caregivers. RESULTS: The median estimated costs to patients and the health service at 2008–9 prices were: Campylobacter £50 million (95% CI: £33m–£75m), norovirus £81 million (95% CI: £63m–£106m), rotavirus £25m (95% CI: £18m–£35m). The costs per case were approximately £30 for norovirus and rotavirus, and £85 for Campylobacter. This was mostly borne by patients and caregivers through lost income or out-of-pocket expenditure. The cost of Campylobacter-related Guillain-Barré syndrome hospitalisation was £1.26 million (95% CI: £0.4m–£4.2m). CONCLUSIONS: Norovirus causes greater economic burden than Campylobacter and rotavirus combined. Efforts to control IID must prioritise norovirus. For Campylobacter, estimated costs should be considered in the context of expenditure to control this pathogen in agriculture, food production and retail. Our estimates, prior to routine rotavirus immunisation in the UK, provide a baseline vaccine cost-effectiveness analyses. Public Library of Science 2016-02-01 /pmc/articles/PMC4735491/ /pubmed/26828435 http://dx.doi.org/10.1371/journal.pone.0138526 Text en © 2016 Tam, O’Brien http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tam, Clarence C
O’Brien, Sarah J
Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title_full Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title_fullStr Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title_full_unstemmed Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title_short Economic Cost of Campylobacter, Norovirus and Rotavirus Disease in the United Kingdom
title_sort economic cost of campylobacter, norovirus and rotavirus disease in the united kingdom
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735491/
https://www.ncbi.nlm.nih.gov/pubmed/26828435
http://dx.doi.org/10.1371/journal.pone.0138526
work_keys_str_mv AT tamclarencec economiccostofcampylobacternorovirusandrotavirusdiseaseintheunitedkingdom
AT obriensarahj economiccostofcampylobacternorovirusandrotavirusdiseaseintheunitedkingdom